{"schema_version":"secwatch.filing_event.v1","accession":"0001731122-22-000470","form_type":"8-K","ticker":"KAVL","cik":"0001762239","company_name":"Kaival Brands Innovations Group, Inc.","filed_at":"2022-03-17T23:59:59+00:00","discovered_at":"2026-05-14T18:04:08.115840+00:00","generated_at":"2026-06-26T22:04:04.781351+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Kaival Brands Q1 revenue plunges 93% to $2.8M; net loss $2.8M; FDA stay granted","bullets":["Revenue $2.8M vs $37.4M YoY, down 93% due to FDA MDO and competition.","Net loss $2.8M ($0.09 loss per share) vs net income $0.3M ($0.01 EPS) YoY.","Gross loss $700K (negative 24.3% margin) vs $4.8M gross profit (11.2% margin) YoY.","Judicial stay of FDA Marketing Denial Order granted Feb 1, 2022; expects to resume flavored BIDI Stick sales.","Regained Nasdaq minimum bid price compliance on Feb 18, 2022."],"urls":{"canonical":"https://secwatch.observer/filing/0001731122-22-000470","json":"https://secwatch.observer/filing/0001731122-22-000470.json","markdown":"https://secwatch.observer/filing/0001731122-22-000470.md","text":"https://secwatch.observer/filing/0001731122-22-000470.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1762239/000173112222000470/0001731122-22-000470-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1762239/000173112222000470/e3621_8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-26T22:04:04.781351+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}